Dianthus price target raised to $125 from $62 at Oppenheimer

Oppenheimer raised the firm’s price target on Dianthus (DNTH) to $125 from $62 and keeps an Outperform rating on the shares. The firm notes dianthus shares have jumped off the starting line this year, up 22% vs. XBI’s 5% following CEO Marino Garcia’s commentary at January’s annual healthcare conference on potential superiority vs. competitor complement inhibitors, and pricing expectations. Oppenheimer caught up with management ahead of the 2026 setup and sees substantial value creation ahead.